18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG
M.D. Anderson Cancer Center
110 participants
Feb 15, 2022
INTERVENTIONAL
Conditions
Summary
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo 18F-FSPG PET scan
Undergo 11C-acetate PET scan
Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
Correlative studies
Undergo 18F-FDG PET scan
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02379377